Kenji Koneri

Kenji Koneri

Auto-generated profile, based on publicly available information

Kenji Koneri

First Department of Surgery, University of Fukui, 23-3 Eiheiji-cho, Yoshida-gun, Fukui 9101193, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2007
Verified
Journal Article
Closed access
KKKenji Koneri
Kenji Koneri
TGTakanori Goi
Takanori Goi
YHYasuo Hirono
Yasuo Hirono
KKKanji Katayama
Kanji Katayama
AYAkio Yamaguchi
Akio Yamaguchi

1 January 2013 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
KKKenji Koneri
Kenji Koneri
YHYasuo Hirono
Yasuo Hirono
DFDaisuke Fujimoto
Daisuke Fujimoto
KSKatsuji Sawai
Katsuji Sawai
MMMitsuhiro Morikawa
Mitsuhiro Morikawa
AYAkio Yamaguchi
Akio Yamaguchi
Koneri K, et al. J Gastric Cancer. 2013 Mar;13(1):58-64. http://dx.doi.org/10.5230/jgc.2013.13.1.58

13 February 2013 in SpringerPlus
Verified
Journal Article
Open access
PDF file
HMHiroyuki Maeda
Hiroyuki Maeda
SYShigehiro Yokoi
Shigehiro Yokoi
MNMasako Nakazawa
Masako Nakazawa
KKKenji Koneri
Kenji Koneri
YIYoshiaki Imamura
Yoshiaki Imamura
AYAkio Yamaguchi
Akio Yamaguchi
Adenomyoepithelial adenosis of the breast is an extremely rare type of adenosis. We herein present the case of a 35-year-old woman, who presented with a small painless hard lump and elastic soft induration of 5 cm in diameter in her left breast. Clinical examination and diagnostic workup were suggestive of a breast carcinoma, and a modified radical mastectomy and sentinel node biopsy were performed. Histopathological examination revealed adenomyoepithelial adenosis along with fibrocystic change and small invasive ductal carcinoma, slightly away from the adenosis. The presented case was thought to be initial-stage adenomyoepithelial adenosis and independently developing breast cancer. From a review of five reported cases of adenomyoepithelial adenosis, complete resection of the tumor and coexisting malignant disease may be recommended, owing to the tendency to develop breast cancer or malignant adenomyoepithelioma, or recurrence.

Verified
Journal Article
Open access
PDF file
HKHiroko Kono
Hiroko Kono
TGTakanori Goi
Takanori Goi
TMTakayuki Matsunaka
Takayuki Matsunaka
KKKenji Koneri
Kenji Koneri
Multidisciplinary treatment for colorectal cancer (CRC) has undergone significant advances, and molecularly targeted drugs have substantially improved patient prognosis. However, one problem with current molecularly targeted therapeutics is that they must be used in combination with anticancer agents. New molecular targeted therapies that can be used alone are needed. We have previously identified prokineticin1 (PROK1) factor as a therapeutic potential target for CRC. PROK1 factor is involved in the angiogenesis of tissues surrounding CRC tumors. Additionally, PROK1 receptors 1 and 2 are expressed in CRC cell lines, playing roles in cell proliferation via an autocrine mechanism and in the signaling system. In this study, a liver metastasis mouse model was developed using human colorectal cancer cell lines, and mice were divided into anti-PROK1 antibody administration and control groups. Mice were treated intraperitoneally with antibodies or phosphate-buffered saline (control) every three days. The number, size, and cell proliferation ability of metastatic lesions were analyzed. Our results suggested that the number, size, and cancer cell proliferation ability of metastatic lesions decreased, and the survival time significantly increased in the antibody-treated group compared to those in the control group. Thus, the anti-PROK1 antibody therapy suppressed the cell proliferation ability of liver metastatic lesions in a CRC mouse model, suggesting its potential as a novel treatment strategy.

20 June 2022 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
KSKatsuji Sawai
Katsuji Sawai
TGTakanori Goi
Takanori Goi
NTNoriyuki Tagai
Noriyuki Tagai
HKHidetaka Kurebayashi
Hidetaka Kurebayashi
MMMitsuhiro Morikawa
Mitsuhiro Morikawa
HMHiroyuki Maeda
Hiroyuki Maeda
Background: Currently, no established standard treatment exists for metastatic anal squamous cell carcinoma. We report a case of complete response in a patient with stage IV anal squamous cell carcinoma after undergoing multidisciplinary treatment. Case presentation: A 62-year-old woman visited a nearby doctor with a chief concern of severe pain associated with a firm mass in the anus. The patient was diagnosed with anal canal squamous cell carcinoma and liver metastases and referred to First Department of Surgery Faculty of Medicine University of Fukui for treatment. The patient received a TNM classification of T4N0M1 and stage IV. Rectal amputation was performed; however, postoperative complications hindered immediate anticancer therapy and the liver metastases exacerbated. Radiofrequency hyperthermia and systemic chemotherapy were performed 3 months postoperatively. A prominent reduction in the liver metastasis was observed. Lung metastases appeared during the course of systemic chemotherapy. Radiotherapy was performed to treat the lung lesion and resolved. Radiotherapy was also performed for liver metastasis. The lesion in the liver showed resolution after 54 months postoperatively, and treatment with the anticancer drug was discontinued. Ten-year follow-up findings suggested complete resolution of the lesion in response to the treatment protocol followed in this case. This long-term survival was achieved through a multidisciplinary treatment. Conclusions: The present case suggests that multidisciplinary treatment approach is effective for resolving stage IV anal squamous cell carcinoma, and addition of new anticancer drug therapy may improve the overall prognosis of squamous cell carcinoma.